Taken together, our data suggests ST6GAL1 may be upregulated in patients with prostate cancer that have increased risk of metastasis, those developing relapse to castrate-resistant disease, and patients with prostate tumours that have spread to the bone. Here, ST6GAL1 is linked to prostate neoplasm.